Upload
others
View
10
Download
0
Embed Size (px)
Citation preview
PARKINSON’S PROGRESSION MARKERS INITIATIVE
PPMI 2018 Annual Investigators Meeting PPMI Data Blitz
2
• Longitudinal Change of Clinical and Biological Measures in Early PD Presented by Andrew Siderowf (on behalf of Tanya Simuni)
• Cognitive-Psychiatric Disorders: Progression and Predictors Presented by Dan Weintraub
• Longitudinal alpha-synuclein measurements in CSF Presented by Brit Mollenhauer
• Two and Four Year Longitudinal Assessment of DAT Imaging Biomarkers Presented by John Seibyl
• Innovative Statistical Design and Analysis in PD Presented by Chris Coffey
• The Future of Clinical Trials Presented by Karl Kieburtz
• Baseline Predictors of Disease Progression Presented by Andrew Siderowf
OVERVIEW
How can PPMI study inform the design of Parkinson’s disease clinical trials
PPMI 5 year longitudinal data THANK YOU
Tanya Simuni, MD on behalf of PPMI Consortium Parkinson’s Disease and Movement Disorders Center
Northwestern UniversityParkinson Foundation Center of Excellence
6
CHANGE IN MDS-UPDRS TOTAL SCORE FROM BL TO YEAR 1 IN PD SUBJECTS
Subjects that completed BL and Year 1 Visits p-value
Variable All PD Untreated Treated with Treated with Untreated vs. Untreated vs. Levodopa/DA
Subjects at Year 1 Levodopa/DA at Year 1
Other PD Med at Year 1
Levodopa/DA Other vs. Other
(N = 393) (N = 162) (N = 165) (N = 66)
Change in MDS-UPDRS Total Score
<.0001 0.0406 0.0047
N Completed 334 162 106 66
Mean (SD) 7.45 (11.6) 10.73 (10.7) 2.41 (11.4) 7.48 (11.2)
(Min, Max) (-31.0, 60.0) (-17.0, 60.0) (-31.0, 32.0) (-19.0, 41.0)
*Time to evaluation was not collected at the 6 month visit*
Variable Time to OFF Score at Year 16-12 Hours >12 Hours p-value
Change in MDS-UPDRS Total Score 0.4718N Completed 25 81Mean (SD) 0.96 (13.6) 2.85 (10.7)(Min, Max) (-18.0, 31.0) (-31.0, 32.0)
*Treatment status for this analysis is defined as treatment with either levodopa or dopamine agonists*
Year 1 Change in MDS-UPDRS Total Scores by Time to OFF Evaluation in
Treated PD Subjects
MDS-UPDRS OFF vs. ON in Treated PD Subjects
05
101520253035404550
Year 1 Year 2
Tota
l MD
S Sc
ores
Axis Title
Total MDS Scores OFF vs. ON Totals in Treated PD Subjects
Levodopa/DA OFF Levodopa Only OFF
Levodopa/DA ON Levodopa ON
N ParticipantsTreated with Levodopa/DA
Treated with Levodopa Only
OFF ON Off ON
Year 1 106 154 41 73
Year 2 163 235 81 105
P ValuesTreated with Levodopa/DA
Treated with Levodopa only
Year 1 Total 0.076 0.1237Year 1 Part III 0.0055 0.0063Year 2 Total 0.0001 0.005Year 2 Part III <.0001 0.0001
05
101520253035404550
Year 1 Year 2
Part
III M
DS
Scor
es
Axis Title
Part III MDS Scores OFF vs. ON in Treated PD Subjects
Levodopa/DA OFF Levodopa Only OFF
Levodopa/DA ON Levodopa ON
10
SUMMARY OF THE RESULTSSO WHAT ???
»Unique dataset that provides data on the natural Hx of PD progression using clinical scales, imaging and biologics
»Essential data for design of future disease modification trials
»Data completeness is essential for the utility of the dataset
»Thank you !!!!–Coordinators /Investigators –Participants
11
QUESTIONS?
Cognitive-Psychiatric Disorders:
Progression and Predictors
Daniel Weintraub, MD
PD Cognition Over Time
Data courtesy Chelsea Caspell-Garcia.
VariablePD Subjects
Baseline Year 1 Year 2 Year 3 Year 4 Year 5(N = 423) (N = 395) (N = 378) (N = 366) (N = 346) (N = 289)
MOCAN 420 392 374 363 341 283Mean (SD) 27.13 (2.3) 26.30 (2.8) 26.28 (3.2) 26.40 (3.0) 26.43 (3.6) 26.58 (3.6)(Min, Max) (17.0, 30.0) (15.0, 30.0) (9.0, 30.0) (13.0, 30.0) (11.0, 30.0) (2.0, 30.0)
MOCA <26N 420 392 374 363 341 283No 327 (77.9%) 257 (65.6%) 253 (67.6%) 246 (67.8%) 238 (69.8%) 205 (72.4%)Yes 93 (22.1%) 135 (34.4%) 121 (32.4%) 117 (32.2%) 103 (30.2%) 78 (27.6%)
MOCA <21N 420 392 374 363 341 283No 416 (99.0%) 379 (96.7%) 354 (94.7%) 349 (96.1%) 320 (93.8%) 266 (94.0%)Yes 4 (1.0%) 13 (3.3%) 20 (5.3%) 14 (3.9%) 21 (6.2%) 17 (6.0%)
2 scores >1.5 SD below meanN 419 393 374 363 338 277Yes 46 (11.0%) 56 (14.2%) 49 (13.1%) 55 (15.2%) 49 (14.5%) 37 (13.4%)
Site Investigator DiagnosisN 106 271 370 364 340 278Normal 97 (91.5%) 231 (85.2%) 309 (83.5%) 284 (78.0%) 265 (77.9%) 222 (79.9%)Mild Cognitive Impairment 9 (8.5%) 38 (14.0%) 58 (15.7%) 74 (20.3%) 63 (18.5%) 46 (16.5%)Dementia 0 (0.0%) 2 (0.7%) 3 (0.8%) 6 (1.6%) 12 (3.5%) 10 (3.6%)
Comments• Highly educated, motivated and relatively young cohort
• Raises possibility of practice effects and temporary positive impact of introduction of PD meds on cognition
• Good cohort for studying resiliency to cognitive decline• Hopefully dropouts aren’t differentially cognitively impaired
• For dementia• Apply more stringent cut-off for MoCA (<21)• Subset of patients developing significant cognitive
impairment relatively quickly• For MCI
• Apply site investigator diagnosis• Consider using HC norms instead of published norms• Years 5-10 data will be more informative
• Mean age by year 10 will be 72, likely an inflection point
Supporting Evidence
Wyman-Chick. Movement Disorders 2018;10.1002/mds.27335. Pigott et al. Neurology 2015;85:1276-1282.
PD Psychiatric Symptoms Over TimeVariable Baseline Year 1 Year 2 Year 3 Year 4 Year 5
PD Subjects (N = 423) (N = 398) (N = 378) (N = 366) (N = 348) (N = 293)GDS-15
N 423 395 376 366 343 286Not Depressed (<5) 364 (86.1%) 330 (83.5%) 309 (82.2%) 304 (83.1%) 283 (82.5%) 228 (79.7%)Depressed (≥5) 59 (13.9%) 65 (16.5%) 67 (17.8%) 62 (16.9%) 60 (17.5%) 58 (20.3%)
STAI-StateN 422 395 377 364 343 286Score <45 358 (84.8%) 343 (86.8%) 332 (88.1%) 321 (88.2%) 302 (88.0%) 252 (88.1%)Anxious (≥45) 64 (15.2%) 52 (13.2%) 45 (11.9%) 43 (11.8%) 41 (12.0%) 34 (11.9%)
QUIPN 422 395 377 366 343 285No Disorders 335 (79.4%) 342 (86.6%) 301 (79.8%) 281 (76.8%) 257 (74.9%) 210 (73.7%)ICD behaviors (≥1) 87 (20.6%) 53 (13.4%) 76 (20.2%) 85 (23.2%) 86 (25.1%) 75 (26.3%)
MDS-UPDRS Part I ApathyN 423 395 377 366 343 2880-1 412 (97.4%) 366 (92.7%) 342 (90.7%) 338 (92.3%) 309 (90.1%) 251 (87.2%)>1 (Apathy) 11 (2.6%) 29 (7.3%) 35 (9.3%) 28 (7.7%) 34 (9.9%) 37 (12.8%)
MDS-UPDRS Part I PsychosisN 423 395 377 366 343 2880-1 423 (100.0%) 395 (100.0%) 373 (98.9%) 361 (98.6%) 336 (98.0%) 281 (97.6%)>1 (Psychosis) 0 (0.0%) 0 (0.0%) 4 (1.1%) 5 (1.4%) 7 (2.0%) 7 (2.4%)
Healthy Controls (N = 196) (N = 185) (N = 174) (N = 167) (N = 162) (N = 140)GDS-15
Depressed (≥5) 13 (6.6%) 10 (5.4%) 8 (4.6%) 7 (4.2%) 5 (3.1%) 9 (6.6%)STAI-State
Anxious (≥45) 9 (4.6%) 11 (5.9%) 6 (3.4%) 5 (3.0%) 7 (4.3%) 6 (4.4%)QUIP
ICD behaviors (≥1) 37 (18.9%) 37 (20.0%) 29 (16.7%) 27 (16.2%) 24 (14.8%) 21 (15.3%)MDS-UPDRS Part I Apathy
>1 1 (0.5%) 1 (0.5%) 1 (0.6%) 2 (1.2%) 1 (0.6%) 1 (0.7%)MDS-UPDRS Part I Psychosis
>1 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Comments• Disorders
• Depression and Apathy: increasing over time• Anxiety: puzzling, but little non-motor fluctuations in
early PD• ICDs and Psychosis: dopamine agonists less
commonly used as initial therapy, long lag time after starting medications (ICDs), cognitively healthy group (psychosis)
• Comparing change in rates over time in PD relative to healthy controls of value• Depression goes from 2x-3x as common in PD as
HCs
Biomarker Definition of cognitive impairmentMoCA<26 or
Change in MoCA scoreCognitive test deficits
(≥2 tests >1.5 SD below mean)
Site investigator diagnosis(PD-MCI or PDD)
DAT imaging - - ↓ ipsilateral caudate*
↓ contralateral caudate§
↓ contralateral putamen§
CSF - - ↓ CSF Aβ 1-42*
Structural MRI (volume)
↓ entorhinal*
↓ superior temporal*§
↓ caudal middle frontal§
↓ lateral orbitofronal§
↓ superior parietal§
- ↓ lateral occipital*
↓ lateral orbitofrontal*
↓ fusiform*§
↓ superior temporal§
Structural MRI(thickness)
↓ precentral§ - ↑ caudal anterior cingulate§
↓ fusiform§
DTI (FA) - - -DTI (MD) - - ↓ inferior cerebellar
peduncle*
Genetics - - COMT val158met (val/val)BDNF val66met (val/val)
Caspell-Garcia et al. PLoS ONE 2017;12(5): e0175674.
# Significant in univariate analysis, survived FDR correction, and significant in multivariable analysis* Baseline biomarker value§ Longitudinal biomarker value
Predicting Future Psychosis in Early PD
19
Reports of Psychotic Symptoms, n
Characteristic 0 (n=285) 1 (n=54) ≥2 (n=84) P value
Scales for Outcomes in Parkinson’s Disease—Autonomic, mean (SD)
8.5 (5.5) 10.2 (6.3) 12.2 (6.5) <0.0001
REM Sleep Behavior Disorder Screening Questionnaire Median Score (IQR) 3 (2-5)* 3.5 (2-6) 5 (3-7)** 0.0003Score >5, n (%) 91 (32.2)* 21 (38.9) 46 (55.4)** 0.001
Epworth Sleepiness Scale Median Score (IQR) 5 (3-8) 5 (3-7) 6 (3-10) 0.03Score ≥0, n (%) 34 (11.9) 6 (11.1) 26 (31.0) <0.001
*n=283.**n=83.
Adjusted for age and sex in multivariate regression, the following baseline symptoms were associated with increased risk of reporting psychotic symptoms on ≥2 occasions:
Greater autonomic symptoms (OR 1.07, P=0.002)
Presence of REM sleep behavior disorder (OR 1.9, P=0.021)
Excessive daytime sleepiness (OR 2.5, P=0.003)
Barrett et al. Neurology. 2018;10.1212/WNL.0000000000005421.
IQR, interquartile range; OR, odds ratio; REM, rapid eye movement; SD, standard deviation
P=0.02
P=0.51
P=0.04
P=0.31
P=0.67
P=0.17
Cholinergic nucleus 4 Cholinergic nuclei 1, 2, and 3
SSRI Use and Cognitive Decline
20Kotagal et al. Annals Neurology. 2018;10.1002/ana.25236.
Hypothesis: Serotonin may modulate Aβ metabolism through up-regulation of alpha-secretase
21
QUESTIONS?
PARKINSON’S PROGRESSION MARKERS INITIATIVE
PPMI Data BLITZLongitudinal alpha-synuclein measurements in CSF
Brit Mollenhauer and Douglas Galasko, Biologics Working Group
0 12 24 36 48 60
Month
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Mea
n St
riatu
m
Report generated on data submitted as of: 04Apr2016
Mean for SWEDD SubjectsMean for Healthy ControlsMean for PD Subjects
Mean Striatum over time
NOTE: Points are only plotted if 5 or more subjects have data at that visit.
23
TRACKING PROGRESS IN TRACKING PARKINSON‘S
0 12 24 36 48 60
Month
0
5
10
15
20
25
30
35
40
45
50
55
60
MD
S-U
PDR
S To
tal S
core
Report generated on data submitted as of: 04Apr2016
Mean for SWEDD SubjectsMean for Healthy ControlsMean for PD Subjects ONMean for PD Subjects OFF
MDS-UPDRS Total Score over time
NOTE: Points are only plotted if 5 or more subjects have data at that visit.
Parkinson‘s disease is a progressing disorder bymotor and non-motor symptoms and dopamine transporter imaging
0 6 12 24 36 48 60
Month
1600
1700
1800
1900
2000
2100
2200
2300
Alph
a-Sy
nucle
in
Report generated on data submitted as of: 13Apr2015
Mean for SWEDD SubjectsMean for Healthy ControlsMean for PD Subjects
Alpha-Synuclein over time
NOTE: Points are only plotted if 5 or more subjects have data at that visit.
0 6 12 24 36 48 60
Month
30
35
40
45
50
55
60
Tau
Report generated on data submitted as of: 13Apr2015
Mean for SWEDD SubjectsMean for Healthy ControlsMean for PD Subjects
Tau over time
NOTE: Points are only plotted if 5 or more subjects have data at that visit.
0 6 12 24 36 48 60
Month
300
325
350
375
400
425
450
A-b
eta
Report generated on data submitted as of: 13Apr2015
Mean for SWEDD SubjectsMean for Healthy ControlsMean for PD Subjects
A-beta over time
NOTE: Points are only plotted if 5 or more subjects have data at that visit.
But there is no PD specific progression in biochemical markers in the cerebrospinal fluid in 12 months
24
DISCREPANCY OF CSF ALPHA-SYNUCLEIN MEASUREMENTSBETWEEN 2013 AND 2016 RE-ANALYSIS OF SAMPLES
Possible reasons for this discrepancy:-preanalytical sample handling (e.g. gradient effect)-analytical variability (non-automated performance of >50 96 well plate ELISA)-other reasons
25
o PD participants who dropped out after baseline had significantly worse cognitive decline shown on HVLT (p=0.039), SDMT (p<0.001), LNS (p=0.031) and in BJLOT (p=0.002).
o Prodromal hyposmic participants with baseline data only had greater cognitive decline (by HVLT; p=0.0007, by SDMT, p=0.045) and lower mean caudate striatal binding ration (SBR) values (p=0.011) on DaTscan.
o iRBD participants with milder iRBD by RBDSQ (<6) were more likely to drop out after baseline assessment (p=0.029).
SECOND LONGITUDINAL ANALYSIS OF CSF ΑLPHA-SYNUCLEIN IN PPMI (MEASUREMENTS OF 2016)
26
Mollenhauer et al., Neurology under review
PPMI: CSF ΑLPHA-SYNUCLEIN RE-ANALYSIS OF 2016 BY ELISA IN(1) PD AND HEALTHY SUBJECTS UNTIL 36 MONTHS FOLLOW-UP(2) IN PRODROMAL SUBJECTS UNTIL 12 MONTHS FOLLOW-UP
1. CSF α-syn levels in PD were significantly lower in across all visits
2. CSF total α-syn levels in PD decreased slightly (p=0.031); levels showed a trend to increase in the control group (p=0.054).
3. Prodromals: The hyposmic participants showed the lowest mean CSF α-syn levels, while iRBD participants had intermediate levels.CSF α-syn remained relatively stable over time.
3. Changes in CSF α-syn were not related to changes in MDS-UPDRS III, MoCA and DaTscan values (p>0.05) in PD
4. We again found a longitudinal relationship between CSF α-syn and LED based on dopamine replacement (p=0.023) (not just dopamine agonists, p=0.145)
5. No association with genetic variants and SNCA transcripts
27
QUESTIONS?
Two and Four Year Longitudinal Assessment of DAT Imaging Biomarkers in a Progressing Parkinson Disease Cohort: Implications for Clinical Trial Design
John P Seibyl, MD on behalf of the PPMI Investigators
Institute for Neurodegenerative Disorders, and Invicro, New Haven, United States
411
PPMI Annual Meeting 2018Data Blitz
Measuring DAT changes in de novo PD with 123-I Ioflupane SPECT over four years
RATIONALE: Prior studies show loss of striatal signal Parkinson's patients studied longitudinally with 123-I Ioflupane SPECT. These studies demonstrate annual loss approximately 7 to 10% of SBR per year, but with significant between subject variance. The purpose of the present investigation was to evaluate different analytic approaches in a large PD cohort studied over four years with serial DAT SPECT.
RESEARCH QUESTIONS:1. Do analytic strategies incorporating curve fitting applied to serial
within subject longitudinal SBR data increase the signal size and reduce the variance compared with standard baseline-follow-up SBR change measures?
2. What are the implications of scan analysis method on clinical therapeutic trial design and sample size estimates?
• 343 PD patients in PPMI had serial ioflupane SPECT scans at baseIine, 1, and 2 years post enrollment, 271 PD patients had an additional 4 year scan
• Employed small region of interest template previously described for developing regional specific binding ratios (SBR).
• Strategies to measure SBR change follows two approaches.
METHODS
Method 1 Standard analysisDelta SBR= - SBR(y0)-SBR(y4)% change = delta SBR/SBR(y0)
Method 2 Exponential fitDelta and % change from equation
ANALYSIS METHODS
Years post Baseline Scan
Compare variance and signal:noise for each measure as well as strength of correlation with motor symptoms and power analyses for detecting change in clinical trials.
Mean Regional Percent Change SBR by Analysis Method
- 4 0
- 2 0
0
2 0
4 0
% c h a n g e b y r e g i o n / a n a l y s i s
% C
ha
ng
e S
BR
S t d 2 Y
S t d 1 Y
E x p 2 Y
n = 3 4 3 2 y
n = 2 7 1 4 y
i c c c i a p c a p i p c p i s c s m s
i = i p s i l a t e r a l
c = c o n t r a l a t e r a l
f o l l o w e d b y
c = c a u d a t e
a p = a n t . p u t a m e n
p = p u t a m e n
s = s t r i a t u m
m s = m e a n s t r i a t u m
S t d 1 Y S D
S t d 2 Y S D
E x p 2 Y S D
S t d 4 Y
E x p 4 y
S t d 4 y s d
E x p 4 Y s d
MeansSD
Sample Size Estimates by Striatal Region, Trial Duration, and Analysis Method
Observations:- Exp analysis better than
std- % change better than
delta SBR at 2,4 y, but not 1 y
- Ipsi better than contra- Contra put worst
I PS
I CA
UD
CO
NT
RA
CA
UD
I PS
I A P
CO
NT
RA
AP
I PS
I PU
T
CO
NT
RA
PU
T
I PS
I ST
RI A
CO
NT
RA
ST
RI A
ME
AN
ST
RI A
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
2 0 0 04 0 0 06 0 0 08 0 0 0
1 0 0 0 0
S a m p l e s i z e b y r e g i o n
Sa
mp
le
s
iz
e
S t d 1 y d
S t d 1 y %
S t d 2 y d
S t d 2 y %
S t d 4 y d
E x p 2 y d
E x p 4 y d
S t d 4 y %
E x p 2 y %
E x p 4 y %
A S S U M E S : 5 0 % e f f e c t s i z e
8 0 % p o w e r , p < 0 . 0 5 , 2 - t a i l e d
St d
1 y
d
St d
1 y
%
St d
2 y
d
St d
2 y
%
St d
4 y
d
St d
4 y
%
Ex
p2
y d
Ex
p2
y %
Ex
p 4
y d
Ex
p 4
y %
VM
AT
2Y
0
5 0
1 0 0
1 5 0
2 0 0
P e r c e n t 2 Y s a m p l e s i z e%
2
y
S
am
pl
e
Best Sample Size Estimate by Method, Normalized to 2 Y Standard Analysis
Delta SBR are green% Change SBR are blueBest region used
N=17
- 5 0 5 1 0
1
2
3
4
M e a n c u r v e s ( n = 2 7 1 , 4 Y d a t a )
Y E A R SS
BR
I P C A
C C A
I P A P
C A P
I P P
C P
S h i f t ( y )
0
1 . 5
3 . 0
6 . 0
7 . 0
1 0 . 5
Regional striatal SBR based on based on monexponential curve fits of 4 year, 4 scan data extrapolating 6 y prior and 11 y post baseline shows similar curves apparently phase shifted
Shifting the curves back to right such that they overlap results in an estimate of the years that region is ahead in the neurodegenerative process relative to ipsilateral caudate.
- 5 0 5 1 0
1
2
3
4
M e a n c u r v e s ( n = 2 7 1 , 4 Y d a t a )
Y E A R S
SB
R
I P C A
C C A
I P A P
C A P
I P P
C P
Conclusions
1. Exponential curve fitting analysis of serial longitudinal DAT SPECT results in similar change in SBR signal as the standard analysis, but with much less noise.
2. This permits sample sizes for the exponential analysis to be roughly half that of the standard analysis for comparable power for detecting a 50% slowing in rate of decline in a treatment v placebo cohort.
3. Different striatal sub-regions show better (ipsi striatum, ipsi ant putamen, mean striatum) or worse (contra putamen) power based on their signal to noise characteristics.
4. The different outcome measures, delta SBR v % change SBR, provide comparable power for the standard analysis, but the % change outcome is more robust with the exponential method.
5. Preliminary VMAT PET in a limited n shows great promise.6. Finally, speculative extrapolation of mean striatal subregion exponential
curves suggest a 10.5 year “head start” in SBR signal change for contra putamen over ipsi caudate.
37
QUESTIONS?
INNOVATIVE STATISTICAL DESIGN & ANALYSIS IN PD
Christopher S. CoffeyDepartment of Biostatistics
University of Iowa
May 02, 2018
The traditional approach to clinical trials tends to be large, costly, and time-consuming.There is a need for more efficient clinical trial design, which should lead to an increased chance of a “successful” trial that answers the question of interest.Hence, there is increasing interest in innovative trial designs.For example, adaptive designs allow reviewing accumulating information during an ongoing clinical trial to possibly modify trial characteristics.
OVERVIEW
39
An adaptive enrichment design fulfills the desire to target therapies to patients who can benefit the most from treatment.The first study period reveals participant groups most likely to benefit from treatment (discovery phase).Subgroup members are then randomized to treatment groups (validation phase).Hence, study power is increased (sample size decreased) by focusing only on subgroups most likely to show benefit.
ENRICHMENT DESIGNS
40
A sample size re-estimation (SSR) design refers to an adaptive design that allows for adjustment of sample size based on a review of the interim data.An internal pilot (IP) design refers to an SSR used to reassess nuisance parameters (only) mid-study.With moderate to large sample sizes, IP designs can be used to make appropriate modifications with minimal (if any) inflation of type I error rate.Thus, there is little reason (statistically) not to do this for most clinical trials!
SAMPLE SIZE RE-ESTIMATION
41
TIMEMean (SD)
Change From Baseline Power
Reduce by 50%
Reduce by 25%
All 7.5 (11.6) 80%90%
310410
12501650
Treated 5.0 (12.0) 80%90%
720960
28503800
Untreated 10.0 (10.6) 80%90%
150200
570760
Hypothetical Early PD Clinical Trial:• Required sample size for detecting change in MDS-
UPDRS OFF scores over 1 year (using PPMI Data)
MDS-UPDRS TOTAL – SAMPLE SIZE
42
Hypothetical Clinical Trial: Power greatly impacted by frequency of subjects
who start therapy within the 1 year period Can base sample size calculation on ‘best guess’ Two adaptive options:
• Enrichment Design: Identify those unlikely to require treatment during first year
• Internal Pilot Design: After some fraction of subjects have completed one year of
follow-up, estimate the percentage starting therapy If different from original assumption, re-estimate sample size
based on revised estimate
MDS-UPDRS TOTAL – SAMPLE SIZE
43
44
QUESTIONS?
THE FUTURE OF CLINICAL TRIALS
CENTER FOR HEALTH + TECHNOLOGYDO THE UNPRECEDENTED
Working to enable anyone, anywhere to receive care, participate in research, and benefit from the resulting advances.
Karl Kieburtz
PPMI PD DRUG VISUALIZATION
Predictive Disease Modeling + Simulation
Work by Monica Javidnia, Chris Snyder, Charles Venuto
PPMI PD DRUG VISUALIZATION (PD-RX)
47
PPMI PD DRUG VISUALIZATION (PD-RX)
Work by Monica Javidnia, Chris Snyder, Charles Venuto
Levodopa/Carbidopa (28%)Levodopa/Carbidopa dose adjustment (15%)Rasagiline (1.5%)
48
PREDICTING DISEASE PROGRESSION
Random Forest models constructed from PPMI to predict future MDS-UPDRS Part III scores
Work by Sam Lerman, Charles Venuto
49
EMERALD PDLeveraging Technology to Advance Care + Research
IN COLLABORATION WITH MIT, WE ARE NOW USING CELLULAR WAVES TO MONITOR GAIT AND MOVEMENT
Emerald-PD Overview:• We enrolled 7 participants with PD• Participants’ homes were fitted
with the Emerald device and observed for 8 weeks
• Aims of the study:• Assess ability of device to
measure disease features in the home
• Develop algorithms to characterize abnormal movements
• Assess response to medication
• Detect and quantify previously unmeasured symptoms
• Measure gait, sleep, and bathroom usageSource: http://www.emeraldforhome.com/
51
THE EMERALD DEVICE CAPTURES NOVEL DISEASE FEATURES IN REAL TIME
Source: Tarolli et al., in development (confidential)
Confidential
52
WE ARE DISCOVERING TRENDS IN SLEEP IN PD THAT WERE NOT PREVIOUSLY KNOWN
Midnight
Noon
Blue = time in bed
Red = large movements
53
54
QUESTIONS?
Baseline Predictors of Disease Progression by Andrew Siderowf
LIST OF BASELINE PREDICTORS AND OUTCOMES
Outcome Baseline predictor
Gender(male) UPSIT SCOPA-
AUTClinical site ESS RBDSQ
Total on 0.0626 NS 0.0573 NS NS NS
Total off 0.0311 0.079 NS NS NS NS
Part 3 on NS NS NS 0.0174 0.0833 NS
Part 3 off NS NS NS 0.0246 NS NS
Mean striatum NS NS NS NS NS <0.0001
Mean putamen NS NS NS NS NS 0.0039
SIGNIFICANT CLINICAL PREDICTORS ACROSS MODELS
Outcome Baseline predictorabeta mean striatum
Total on 0.0461 NS
Total off 0.0153 0.0733
Part 3 on 0.0417 NS
Part 3 off 0.0284 0.0469
Mean striatum 0.0531 NA
Mean putamen 0.06393 0.0662
SIGNIFICANT BIOMARKER PREDICTORS ACROSS MODELS
CHANGE IN STRIATAL DAT AND OFF UPDRS AS A FUNCTION OF BASELINE ABETA
-100
-50
050
perc
hg_s
triat
um
0 500 1000 1500 2000bl_abeta
-40
-20
020
4060
chg_
updr
s_to
tsco
re
0 500 1000 1500 2000bl_abeta
60
QUESTIONS?
THANK YOU